Description

VOVERAN SR 75 MG TAB

Indications

VOVERAN SR 75 MG TAB is a medication primarily indicated for the management of pain and inflammation associated with various conditions. It is commonly prescribed for the treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Additionally, VOVERAN may be utilized for the relief of postoperative pain and acute musculoskeletal disorders. The sustained-release formulation allows for prolonged therapeutic effects, making it suitable for chronic pain management.

Mechanism of Action

VOVERAN SR contains the active ingredient Diclofenac Sodium, a non-steroidal anti-inflammatory drug (NSAID). Its mechanism of action involves the inhibition of cyclooxygenase (COX) enzymes, which play a crucial role in the conversion of arachidonic acid to prostaglandins. Prostaglandins are mediators of inflammation, pain, and fever. By reducing the synthesis of these compounds, VOVERAN SR alleviates pain and inflammation, providing symptomatic relief in various conditions.

Pharmacological Properties

VOVERAN SR is characterized by its anti-inflammatory, analgesic, and antipyretic properties. The sustained-release formulation allows for a gradual release of Diclofenac into the bloodstream, maintaining therapeutic levels over an extended period. This pharmacokinetic profile contributes to its efficacy in managing chronic pain conditions. The drug is rapidly absorbed after oral administration, with peak plasma concentrations typically reached within 2 to 4 hours. It is extensively metabolized in the liver, and its metabolites are primarily excreted through the kidneys.

Contraindications

VOVERAN SR is contraindicated in individuals with known hypersensitivity to Diclofenac or any of its components. It should not be used in patients with a history of gastrointestinal bleeding, peptic ulcer disease, or severe renal impairment. Additionally, the medication is contraindicated during the third trimester of pregnancy due to potential risks to the fetus. Patients with a history of asthma, urticaria, or other allergic reactions to NSAIDs should also avoid using VOVERAN SR.

Side Effects

Common side effects associated with VOVERAN SR may include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal pain. Other potential side effects include dizziness, headache, and skin rashes. Serious adverse effects, although rare, can occur and may include gastrointestinal bleeding, liver dysfunction, renal impairment, and cardiovascular events. Patients should be advised to report any unusual symptoms or side effects to their healthcare provider promptly.

Dosage and Administration

The recommended dosage of VOVERAN SR for adults is typically one tablet (75 mg) taken once daily. It is advisable to take the tablet with food to minimize gastrointestinal irritation. The dosage may be adjusted based on individual patient needs and response to treatment. It is essential not to exceed the recommended dose to reduce the risk of adverse effects. For pediatric patients, the safety and efficacy of VOVERAN SR have not been established, and its use is not generally recommended.

Interactions

VOVERAN SR may interact with various medications, potentially altering their effects or increasing the risk of adverse reactions. Co-administration with other NSAIDs, anticoagulants, or antiplatelet agents may enhance the risk of gastrointestinal bleeding. Additionally, the use of VOVERAN SR with certain antihypertensive medications may reduce their efficacy. It is crucial for patients to inform their healthcare provider of all medications they are currently taking, including over-the-counter drugs and supplements, to avoid potential interactions.

Precautions

Patients using VOVERAN SR should be monitored for signs of gastrointestinal bleeding, especially if they have a history of peptic ulcer disease or are concurrently using corticosteroids or other NSAIDs. Caution should be exercised in patients with pre-existing liver or renal conditions, as VOVERAN SR may exacerbate these issues. It is also important to assess cardiovascular risk factors, as NSAIDs have been associated with an increased risk of cardiovascular events. Pregnant women, particularly in the third trimester, should avoid using VOVERAN SR due to potential risks to the fetus.

Clinical Studies

Clinical studies have demonstrated the efficacy of VOVERAN SR in managing pain and inflammation associated with various musculoskeletal disorders. In randomized controlled trials, patients receiving VOVERAN SR reported significant reductions in pain scores and improvements in functional outcomes compared to placebo groups. The sustained-release formulation has been shown to provide effective pain relief with a favorable safety profile when used as directed. Long-term studies have also indicated that VOVERAN SR can be beneficial in maintaining pain control in chronic conditions, enhancing the quality of life for patients.

Conclusion

VOVERAN SR 75 MG TAB is a valuable therapeutic option for the management of pain and inflammation in various conditions, particularly those affecting the musculoskeletal system. Its mechanism of action as a COX inhibitor, combined with its sustained-release formulation, allows for effective and prolonged relief of symptoms. However, careful consideration of contraindications, potential side effects, and drug interactions is essential for safe and effective use. Patients should be adequately informed about the proper use of VOVERAN SR and monitored for any adverse effects during treatment.